Skip to content

Debt-to-assets at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
0.2×+0.1×
Arrowhead Research logo
Arrowhead ResearchARWR
0.0×
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
0.0×
PTC Therapeutics logo
PTC TherapeuticsPTCT
0.1×0.0×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.0×
Scholar Rock logo
Scholar RockSRRK
0.4×+0.2×

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Calculated from Dyne Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s debt-to-assets?
Dyne Therapeutics, Inc. (DYN) reported debt-to-assets of 0.2× in Q1 2026.
How has Dyne Therapeutics, Inc.'s debt-to-assets changed year-over-year?
Dyne Therapeutics, Inc.'s debt-to-assets increased by 382.1% year-over-year, from 0× to 0.2×.
What is the long-term trend for Dyne Therapeutics, Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s debt-to-assets has grown at a 128.3% compound annual growth rate (CAGR), from 0× to 0.1×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.